Equillium, Inc..
EQ.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Equillium, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders. Their lead product candidate, itolizumab, is a monoclonal antibody targeting the CD6 receptor on T cells. Itolizumab is being developed for variou...Show More
Better Health for All
0
No evidence available to assess Equillium, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
Equillium, Inc. is a clinical-stage biotechnology company focused on developing therapeutics.
1
The provided articles contain no evidence that the company offers lending, deposit, or other financial services to consumers or businesses.
2
Consequently, all KPIs related to fair money and economic opportunity, including underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, financial literacy initiatives, debt burden ratio, geographic inclusion, and product simplicity, are not applicable to its core business operations. The company's profit retention policies are standard, with no evidence of reinvestment in community finance or profit-sharing with underserved communities.
3
Fair Pay & Worker Respect
0
No quantitative data is available for any of the KPIs, including living wage coverage, CEO-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.
1
While one article mentions '100% employer-paid health contribution,'
2
it does not specify the percentage of the workforce covered by this benefit, which is required for scoring the health_insurance_coverage KPI.
Fair Trade & Ethical Sourcing
0
No relevant evidence was found in the provided articles for Equillium, Inc. regarding Fair Trade & Ethical Sourcing. The articles provided pertain to Biocon Limited and Biocon Biologics, not the company under assessment.
1
, from equilliumbio.com, explicitly states that no data relevant to EQ.US regarding fair trade & ethical sourcing could be extracted.
2
Honest & Fair Business
0
No relevant data could be extracted from the provided articles to assess Equillium, Inc. against the 'Honest & Fair Business' value.
1
All articles indicated that data access was throttled, preventing retrieval of information.
2
Kind to Animals
0
No evidence available to assess Equillium, Inc. on Kind to Animals.
No War, No Weapons
0
Equillium, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for autoimmune and inflammatory disorders, with no explicit mention of revenue from arms or defense contracts.
1
The company does not develop or sell dual-use technology, nor does it have any exposure to controversial weapons.
2
Its core business activities do not involve defense or arms-related operations, and there is no indication of defense assets requiring divestment.
3
The company's Code of Business Conduct and Ethics outlines policies for legal compliance, including US Embargoes and Export Controls, indicating a commitment to avoiding sales to embargoed regimes.
4
There is no evidence of board oversight related to defense, as the company has no defense business to oversee, and no ethical red lines related to weapons are needed for its business model.
5
The company does not use AI militarily.
6
Planet-Friendly Business
-50
The company does not have a Science Based Target Initiative (SBTi) commitment.
1
No other specific quantitative data related to planet-friendly business metrics, such as greenhouse gas emissions, renewable energy use, water use, or waste diversion, is available.
2
Respect for Cultures & Communities
0
No evidence available to assess Equillium, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess Equillium, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific, quantitative evidence was found in the provided articles for Equillium, Inc. (EQ.US) regarding its waste management practices, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certifications, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education. Articles referring to 'Equilibrium' and its investments are not relevant to Equillium, Inc. (EQ.US), a clinical-stage biotechnology company.